DUBLIN (BUSINESS WIRE) The "Hypoglycemia - Global Drug Forecast and Market Analysis to 2030" report has been added to ResearchAndMarkets.com's offering.This report will focus on diabetic hypoglycemia, and post-bariatric surgery hypoglycemia (PBH). There is currently no approved treatment for PBH.The therapeutic ma.
Share this article
Share this article
ResearchAndMarkets.com s offering.
The MDD market is a crowded and competitive market with a large number of products available for the treatment of patients; the majority of which are available as inexpensive generics.
Major depressive disorder (MDD) is one of the most common psychiatric diseases worldwide, and is characterized by single or recurrent major depressive episodes (MDEs). MDD is only diagnosed if an MDE is not better explained by a psychotic disorder such as schizophrenia, schizoaffective disorder, schizophreniform disorder, delusional disorder, or other psychotic disorder, and if there is no history of hypomania or mania. The term unipolar depressive disorder is often used to distinguish MDD from depressive episodes that occur in conjunction with manic episodes, known as bipolar disorder.
Global Chronic Kidney Disease Anemia Drug Forecast and Market Analysis 2021-2029: Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitors Dominate the CKD Anemia Pipeline prnewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from prnewswire.com Daily Mail and Mail on Sunday newspapers.
Share:
ResearchAndMarkets.com s offering.
Based on epidemiological analysis, the number of diagnosed prevalent cases of T2D will grow by 28.76% over the forecast period, at an AGR of 2.3%, from 164,826,095 cases in 2018 to 216,029,212 cases by 2029 across the nine major pharmaceutical markets covered in this report, the US, 5EU (France, Germany, Italy, Spain and UK), Japan, India and China.
The report projects that the marketplace for T2D within the 9MM will grow from $48bn in 2019 at a compound annual growth rate (CAGR) of 6.7% to $91.9B by 2029. In particular, the report expects the US market will contribute the most to the antidiabetic market s growth, contributing sales in $28B sales in 2019 (58% of the global antidiabetic market) and $57B in 2029 (62% of the global antidiabetic market).